Ghost Tree Capital’s Vaxcyte PCVX Stock Holding History

Ghost Tree Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$9.14M	Sell	80,000 -70,000	-47%	-$6.31M	2.76%	11
2024 Q2	$11.3M	Buy	150,000 +55,000	+58%	+$3.74M	3.55%	8
2024 Q1	$6.49M	Buy	95,000 +25,000	+36%	+$1.73M	1.8%	19
2023 Q4	$4.4M	Sell	70,000 -70,000	-50%	-$3.64M	1.44%	22
2023 Q3	$7.14M	Sell	140,000 -140,000	-50%	-$6.91M	2.35%	12
2023 Q2	$14M	Buy	280,000 +55,000	+24%	+$2.61M	4.62%	6
2023 Q1	$8.43M	Buy	225,000 +65,000	+41%	+$2.76M	2.49%	11
2022 Q4	$7.67M	Sell	160,000 -200,000	-56%	-$7.85M	3.28%	14
2022 Q3	$8.64M	Buy	360,000 +35,000	+11%	+$887K	2.43%	17
2022 Q2	$7.07M	Buy	325,000 +25,000	+8%	+$579K	3.68%	10
2022 Q1	$7.25M	Buy	300,000 +50,000	+20%	+$1.09M	1.57%	14
2021 Q4	$5.95M	Buy	250,000 +90,000	+56%	+$2.09M	2.13%	16
2021 Q3	$4.06M	Buy	160,000 +15,000	+10%	+$364K	1.19%	36
2021 Q2	$3.26M	Buy	+145,000	New	+$2.97M	0.9%	36

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ghost Tree Capital's PCVX Position: Q3 2024 in Review

Ghost Tree Capital reduced its Vaxcyte (PCVX) stake by 47% in Q3 2024, selling an estimated $6.31M and leaving 80,000 shares worth $9.14M. The position accounts for 2.76% of the portfolio, ranked #11.

Ghost Tree Capital first reported a position in PCVX in Q2 2021 and has held it in 14 quarters since. The position peaked at $14M in Q2 2023. 328 funds tracked by Wall St. Rank hold PCVX as of Q3 2024.

Ghost Tree Capital held 80,000 shares of Vaxcyte worth $9.14M as of Q3 2024.
Ghost Tree Capital sold 70,000 Vaxcyte shares in Q3 2024, an estimated $6.31M.
Vaxcyte made up 2.76% of Ghost Tree Capital's portfolio in Q3 2024, its #11 holding.
Ghost Tree Capital first reported a position in Vaxcyte in Q2 2021 and has held it in 14 quarters since.
Ghost Tree Capital's Vaxcyte position peaked at $14M in Q2 2023.
328 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.